140 results on '"Sperinde J"'
Search Results
2. Very high quantitative tumor HER2 content and outcome in early breast cancer
3. Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab
4. Radiological Physics Characteristics of the Extracted Heavy Ion Beams of the Bevatron
5. Improved Delay Lines for Proportional Wire Chamber Readout
6. IMPROVED DELAY LINES FOR PROPORTIONAL WIRE CHAMBER READOUT
7. CHARACTERISTICS OF MULTIWIRE PROPORTIONAL CHAMBERS FOR POSITRON IMAGING
8. ELECTROMAGNETIC DELAY LINE READOUT FOR PROPORTIONAL WIRE CHAMBERS
9. TECHNIQUES FOR MAPPING THE SPATIAL DISTRIBUTION OF STOPPING n"" MESONS IN TISSUE
10. EVIDENCE FOR A LOW-ENERGY RESONANCE IN THE THREE-NEOTRON SYSTEM
11. An Experimental Test of Time-Reversal Invariance inthe Photodisintegration of the Deuteron
12. A METHOD FOR MAPPING THE SPATIAL DISTRIBUTION OF STOPPING n MESONS IN TISSUE
13. A METHOD FOR MAPPING THE SPATIAL DISTRIBUTION OF STOPPING n MESONS IN TISSUE
14. Abstract P1-03-02: ASCO/CAP human epidermal growth factor receptor-2 (HER2) in situ hybridization (ISH) categories evaluated by quantitative HER2 protein diagnostic methodologies: A comparative analysis
15. An Experimental Test of Time-Reversal Invariance in the Photodisintegration of the Deuteron
16. Abstract P2-05-21: Predictive value of quantitative HER2 and HER3 levels combined with downstream signaling markers in HER2-positive advanced breast cancer patients treated with lapatinib
17. Molecular characterization of HER2-positive (HER2+) metastatic gastric and gastro-esophageal junction cancer patients (mGC): Identification of resistance mechanisms to trastuzumab-based therapy (TTZ)
18. Abstract P3-07-09: Quantitative p95HER2 protein expression is predictive of trastuzumab response in HER2-positive metastatic breast cancer
19. Discordant HER2 Total and HER2 Homodimer Levels by HERmark Analysis in Matched Primary and Metastatic Breast Cancer FFPE Specimens
20. Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases
21. 629P - Molecular characterization of HER2-positive (HER2+) metastatic gastric and gastro-esophageal junction cancer patients (mGC): Identification of resistance mechanisms to trastuzumab-based therapy (TTZ)
22. Abstract P6-11-07: Quantitative p95HER2 levels in primary breast cancers and in matched brain metastases
23. Abstract P1-08-23: Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer
24. Abstract P1-08-42: High HER2 expression correlates with response to trastuzumab and the combination of trastuzumab and lapatinib in the NeoALTTO phase III trial
25. Abstract P2-10-31: Correlation of quantitative p95HER2 and total HER2 levels with clinical outcomes in a combined analysis of two cohorts of trastuzumab-treated metastatic breast cancer patients
26. Abstract P2-10-16: Quantitative HER3 protein expression and PIK3CA mutation status in matched samples from primary and metastatic breast cancer tissues and correlation with time to recurrence
27. P2-12-05: Correlation between Quantitative HER2 Protein Expression and Risk of Brain Metastases in HER2−Positive Advanced Breast Cancer Patients Receiving Trastuzumab-Containing Therapy.
28. Mutations of the catalytic domain of PI3 kinase and correlation with clinical outcome in trastuzumab-treated metastatic breast cancer (MBC).
29. Quantitative measurements of p95HER2 (p95) and total HER2 (H2T) protein expression in patients with trastuzumab-treated, metastatic breast cancer (MBC): Independent confirmation of clinical cutoffs.
30. Multiple Subtypes of HER-2/Neu-Positive Metastatic Breast Cancer.
31. Relationship between Quantitative HER2 Protein Expression and Clinical Outcomes in ER-Positive and ER-Negative Sub-Groups of Patients with Trastuzumab-Treated Metastatic Breast Cancer.
32. Discordant HER2 Total and HER2 Homodimer Levels by HERmark Analysis in Matched Primary and Metastatic Breast Cancer FFPE Specimens.
33. Breast Cancer Patients with Very High Tumor HER2 Expression Levels Might Not Benefit from Treatment with Trastzumab Plus Chemotherapy: A Retrospective Exploratory Analysis of the FinHer Trial.
34. Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab
35. Quantitative measurement of HER3 total protein (H3T) and association with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab
36. Quantitative HER2 homodimer levels correlate with time to first recurrence in HER2-positive breast cancer patients who did not receive trastuzumab in the adjuvant setting.
37. HER2 protein expression predicts response to trastuzumab in FISH-positive patients.
38. Use of total HER2 and HER2 homodimer levels to predict response to trastuzumab
39. Quantitative measurement of HER2 expression and HER2 homo-dimerization in formalin-fixed paraffin-embedded (FFPE) breast cancer tissues using a novel proximity-based assay
40. HER2 expression and HER2:HER2 dimerization identifies subpopulations of metastatic breast cancer patients with different probabilities of long-term survival following trastuzumab treatment and with different requirements for concomitant chemotherapy
41. Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2:HER2 dimerization in a clinic-based cohort of patients with metastatic breast cancer
42. IMPROVED DELAY LINES FOR PROPORTIONAL WIRE CHAMBER READOUT.
43. TECHNIQUES FOR MAPPING THE SPATIAL DISTRIBUTION OF STOPPING $pi$$sup -$ MESONS IN TISSUE.
44. A method for mapping the spatial distribution of stopping π - mesons in tissue.
45. Control and Prediction of Gelation Kinetics in Enzymatically Cross-Linked Poly(ethylene glycol) Hydrogels
46. Tresyl-Mediated Synthesis: Kinetics of Competing Coupling and Hydrolysis Reactions as a Function of pH, Temperature, and Steric Factors
47. Synthesis and Characterization of Enzymatically-Cross-Linked Poly(ethylene glycol) Hydrogels
48. A METHOD FOR MAPPING THE SPATIAL DISTRIBUTION OF STOPPING n MESONS IN TISSUE
49. Measurement of radiative pion-proton scattering at backward photon angles
50. Wire spark chambers for clinical imaging of gamma-rays
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.